CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 130 enrolled
Drug / intervention
Apixaban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00320255
NCT00320255Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled Study of Apixaban for the Prevention of Thromboembolic Events in Patients Undergoing Treatment for Advanced Cancer: A Phase 2 Pilot Study

Bristol-Myers Squibb·interventional·Posted May 3, 2006·Updated Aug 16, 2016

In Brief

A Phase 2 clinical trial evaluating Apixaban and Placebo for Thrombosis and 2 related conditions. Completed, enrolled 130 participants across 14 sites in 2 countries.

Detailed Summary

The purpose of this study is to learn whether apixaban is well-tolerated and acceptable as anticoagulant therapy, when administered to patients with advanced or metastatic cancer and at increased risk for venous thromboembolic events. Demonstration of a favorable benefit:risk profile could lead to significant reduction in this serious and sometimes fatal complication of ongoing cancer and its treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThrombosis, Cancer, Pulmonary Embolism
CountriesCanada, United States
CollaboratorsOntario Clinical Oncology Group (OCOG)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 3, 2006
Enrollment StartJun 1, 2006
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 20.2 years ago

Interventions

Apixabandrug

Oral tablets administered once daily in 5-, 10-, or 20-mg dose

Placebodrug

Oral tablets administered once daily